REPL · Company research
Replimune Group, Inc. (REPL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
21records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors | Mestag Therapeutics announced the appointment of Philip Astley-Sparke and Victor Sandor, M.D.C.M. to its Board of Directors. Both appointees bring extensive biotech and oncology development experience. The appointments strengthen the Board as Mestag advances MST-0312, a targeted lymphotoxin-beta agonist bispecific antibody, in the Phase 1 STARLYS trial for patients with advanced solid tumors. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 0.5 | 1 |
| (REPL) Risk Channels and Responsive Allocation - Stock Traders Daily | (REPL) Risk Channels and Responsive Allocation Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 18, 2026 | neutral | 0 | 0.6 |
| Replimune Group: A Hold Until TUDRIQEV’s Commercial Potential Becomes Clear (NASDAQ:REPL) - Seeking Alpha | Replimune Group: A Hold Until TUDRIQEV’s Commercial Potential Becomes Clear (NASDAQ:REPL) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 13, 2026 | neutral | 0 | 0.6 |
| REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome - Stocktwits | REPL Stock Tracks Best Day Ever: This Analyst Sees Higher Approval Odds For Replimune’s Melanoma After ‘Overwhelmingly Positive’ Panel Outcome Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? - Stocktwits | REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Why Did REPL, SNOW, NET Stocks Surge To 52-Week Highs Last Week? - Stocktwits | Why Did REPL, SNOW, NET Stocks Surge To 52-Week Highs Last Week? Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Replimune Group (REPL) Could Be 44% Below Fair Value As TUDRIQEV Launch Begins - Simply Wall Street | Replimune Group (REPL) Could Be 44% Below Fair Value As TUDRIQEV Launch Begins Simply Wall Street | View source ↗ | Simply Wall Street | Oct 10, 2026 | neutral | 0 | 0.6 |
| Replimune Group, Inc. (REPL) Stock Price, News, Quote & History - Yahoo! Finance Canada | Replimune Group, Inc. (REPL) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus - Yahoo Finance | Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Tudriqev Launch Could Matter For Replimune Stock (REPL) - Simply Wall Street | Tudriqev Launch Could Matter For Replimune Stock (REPL) Simply Wall Street | View source ↗ | Simply Wall Street | Oct 8, 2026 | neutral | 0 | 0.6 |
| REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky - PR Newswire | REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Oct 5, 2026 | neutral | 0 | 0.6 |
| REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug - Stocktwits | REPL Stock Rallies In Anticipation Of FDA Decision On Skin Cancer Drug Stocktwits | View source ↗ | Stocktwits | Oct 2, 2026 | neutral | 0 | 0.6 |
| REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th | A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th | A class action lawsuit has been filed against Replimune Group Inc. for allegedly making materially false statements regarding its Biologics License Application (BLA). The lawsuit claims the company failed to disclose that FDA study design concerns were not addressed and that submitted data from an early analysis included only 40 of 400 planned patients, likely causing FDA rejection of the BLA. Investors who purchased securities between October 20, 2025 and April 10, 2026 can apply to be lead plaintiff by October 5, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bearish | -1 | 1 |
| REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky - Morningstar | REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky Morningstar | View source ↗ | Morningstar | Sep 30, 2026 | neutral | 0 | 0.6 |
| REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 - Morningstar | REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 Morningstar | View source ↗ | Morningstar | Sep 24, 2026 | neutral | 0 | 0.6 |
| Melanoma treatment gets FDA accelerated approval; launch expected in 60 days - Stock Titan | Melanoma treatment gets FDA accelerated approval; launch expected in 60 days Stock Titan | View source ↗ | Stock Titan | Aug 14, 2026 | neutral | 0 | 0.6 |
| $REPL stock is up 12% today. Here's what we see in our data. - Quiver Quantitative | $REPL stock is up 12% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 12, 2026 | neutral | 0 | 0.6 |
| REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? - Yahoo Finance | REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 6, 2026 | neutral | 0 | 0.6 |
| Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits | Why Is REPL Stock Soaring 127% After Hours Today? Stocktwits | View source ↗ | Stocktwits | Jul 30, 2026 | neutral | 0 | 0.6 |
| Replimune Shares Crash Following FDA Review of Melanoma Treatment - Pharmaceutical Executive | Replimune Shares Crash Following FDA Review of Melanoma Treatment Pharmaceutical Executive | View source ↗ | Pharmaceutical Executive | Jul 29, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.